A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED

NCT05966493

Status	RECRUITING
Phase	Phase 2
Sponsor	Glaukos Corporation
Enrollment	84 participants

Key Eligibility Criteria

Inclusion (4)

- Have a PCED that is at least 2 weeks in duration and refractory to one or more conventional non-surgical standard of care (SOC) treatments
- Have no clinical evidence of improvement in the PCED within 2 weeks prior to randomization despite the use of non-surgical SOC treatment
- Subject must provide written informed consent (or assent)
- Subjects with childbearing potential must be 1-year postmenopausal, surgically sterilized, or have a negative urine pregnancy test

Exclusion (10)

- Have a known ocular infection that is deemed to be active requiring therapeutic intervention
- Present with a corneal surface defect in either eye that is directly attributed to an infectious etiology (bacterial, viral, fungal and/or protozoal) that has not fully resolved and/or treatment has not been completed
- Present with evidence of corneal ulceration/melting involving the posterior third of the stroma and/or perforation in either eye
- Have a blepharitis or meibomian gland disease in the study eye that is deemed to be clinically relevant and/or active
- Have a history of ocular surgery or any ocular procedure(s) not meeting the designated washout time

... and 5 more (see full listing online)

Locations (28 total)

Glaukos Investigative Site, Dothan, Alabama, United States
Glaukos Investigative Site, Petaluma, California, United States
Glaukos Investigative Site, Torrance, California, United States
... and 25 more locations